Products

Treatment of the following infections of mild to moderate severity in adults:

Lower respiratory tract infections. Acute bacterial bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis.

Community acquired pneumonia due to Streptococcus pneumoniae or Haemophilus influenzae in patients suitable for outpatient oral treatment.

Upper respiratory tract infections. Acute sinusitis due to Streptococcus pneumoniae or Haemophilus influenzae.

Acute streptococcal pharyngitis. Note. Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. Azithromycin appears to be almost as effective in the treatment of streptococcal pharyngitis. However, substantial data establishing the efficacy of azithromycin in the subsequent prevention of rheumatic fever are not available at present.

Uncomplicated skin and skin structure infections. Uncomplicated infections due to Staphylococcus aureus, Streptococcus pyogenes or Streptococcus agalactiae. Abscesses usually require surgical drainage.

Sexually transmitted disease. Uncomplicated urethritis and cervicitis due to Chlamydia trachomatis.

Note. At the recommended dose azithromycin cannot be relied upon to treat gonorrhoea or syphilis. As with other drugs for the treatment of nongonococcal infections, it may mask or delay the symptoms of incubating gonorrhoea or syphilis. Appropriate tests should be performed for the detection of gonorrhoea or syphilis and treatment should be instituted as required.

Azithromycin is also indicated for the treatment of Chlamydia trachomatis conjunctivitis and trachoma.

Azithromycin is also indicated for the prevention of infection due to Mycobacterium aviumintracellulare complex (MAC) disease, when used as the sole agent or in combination with rifabutin at its approved dose, in adults and children aged more than 12 years with HIV infection and CD4 cell count less than or equal to 75 cells/microlitre (see Precautions). Disseminated infection due to Mycobacterium avium-intracellulare complex should be excluded by a negative blood culture prior to commencement of therapy.

Zinc supplement.

• Treatment of schizophrenia and related psychoses. • Short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar I disorder. • Preventing recurrence of manic, mixed or depressive episodes in bipolar I disorder.

Main clinical manifestation sofurate/uric acid deposition. These are gouty arthritis,skin tophi and/or renal involvement through crystal deposition or stone formation. Such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:

• - hypoxanthine guanine phosphoribosyltransferase including Lesch-Nyhan syndrome,
• - lucose 6-phosphatase including glycogen storage disease,
• - phosphoribosylpyrophosphate synthetase,
• - phosphoribosylpyrophosphate amidotransferase.

ZYLOPRIM is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyl transferase.
ZYLOPRIM is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

ZYPREXA is indicated for the treatment of schizophrenia and related psychosis.

ZYPEXA alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with Bipolar I Disorder.

ZYPREXA is indicated for preventing recurrence of manic, mixed or depressive episodes in Bipolar I Disorder.